Arch Biopartners Closes Non-Brokered Private Placement

Executive Summary

• Arch Biopartners closed a non‑brokered private placement of 576,923 common shares at $1.04 CAD per share, raising gross proceeds of $600,000 CAD.
• The raise exceeds the originally disclosed amount by $100,000 CAD and will be used for general working capital and operating expenses not covered by trial funding grants.
• The transaction involved a related‑party purchase (480,923 shares issued to an officer) but is exempt from valuation and minority‑shareholder approval requirements under MI 61‑101.

Key Details

• Offering Size: 576,923 common shares at $1.04 CAD per share.
• Gross Proceeds: $600,000 CAD (CAD $100,000 above the amount initially disclosed on Nov 10, 2025).
• Use of Proceeds: General working capital and certain operating expenses not funded by human‑trial grants.
• Related‑Party Component: 480,923 shares issued to a company officer; qualifies as a related‑party transaction under MI 61‑101 but is exempt from formal valuation and minority‑shareholder approval because consideration does not exceed 25% of market capitalization.
• Holding Period: All shares subject to a lock‑up of four months and one day from the closing date.
• Regulatory Conditions: Closing contingent upon receipt of applicable regulatory approvals, including final TSX Venture Exchange approval.
• Finder’s Fees: None paid in connection with the offering.
• Share Count Post‑Offering: 66,933,289 common shares outstanding.

Notable Quotes

(No executive quotes were included in the release.)